SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Avanos Medical, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Tuesday, 2/20/24, at 6:33pm ET   ·   As of:  2/21/24   ·   For:  12/31/23   ·   Accession #:  1606498-24-18   ·   File #:  1-36440

Previous ‘10-K’:  ‘10-K’ on 2/21/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   18 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/21/24  Avanos Medical, Inc.              10-K       12/31/23  114:10M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.77M 
 2: EX-19.1     Amended and Restated Policy on Insider Trading and  HTML     73K 
                Tipping                                                          
 3: EX-21       Subsidiaries of the Corporation                     HTML     35K 
 4: EX-23       Consent of Independent Registered Public            HTML     30K 
                Accounting Firm                                                  
 5: EX-24       Powers of Attorney                                  HTML     39K 
10: EX-97.1     Incentive Compensation Clawback Policy              HTML     50K 
 6: EX-31.A     Section 302 CEO Certification                       HTML     34K 
 7: EX-31.B     Section 302 CFO Certification                       HTML     34K 
 8: EX-32.A     Section 906 CEO Certification                       HTML     31K 
 9: EX-32.B     Section 906 CFO Certification                       HTML     31K 
16: R1          Cover                                               HTML     97K 
17: R2          Audit Information                                   HTML     35K 
18: R3          Consolidated Income Statements                      HTML    123K 
19: R4          Consolidated Statements of Comprehensive Income     HTML     59K 
                (Loss)                                                           
20: R5          Consolidated Balance Sheets                         HTML    148K 
21: R6          Consolidated Balance Sheets (Parenthetical)         HTML     45K 
22: R7          Consolidated Statement of Stockholders? Equity      HTML     88K 
23: R8          Consolidated Cash Flow Statements                   HTML    119K 
24: R9          Accounting Policies                                 HTML     61K 
25: R10         Discontinued Operations                             HTML     81K 
26: R11         Restructuring                                       HTML     55K 
27: R12         Goodwill                                            HTML     40K 
28: R13         Supplemental Balance Sheet Information              HTML    101K 
29: R14         Business Acquisitions                               HTML     76K 
30: R15         Leases                                              HTML     60K 
31: R16         Fair Value Information                              HTML     52K 
32: R17         Debt                                                HTML     64K 
33: R18         Income Taxes                                        HTML    110K 
34: R19         Employee Benefit Plans                              HTML     37K 
35: R20         Accumulated Other Comprehensive Income              HTML     59K 
36: R21         Stock-Based Compensation                            HTML     86K 
37: R22         Commitments and Contingencies                       HTML     40K 
38: R23         Earnings Per Share ("Eps")                          HTML     61K 
39: R24         Business and Products Information                   HTML     66K 
40: R25         Share Repurchase Program                            HTML     46K 
41: R26         Accounting Policies (Policies)                      HTML     98K 
42: R27         Discontinued Operations (Tables)                    HTML     79K 
43: R28         Restructuring (Tables)                              HTML     49K 
44: R29         Goodwill (Tables)                                   HTML     42K 
45: R30         Supplemental Balance Sheet Information (Tables)     HTML    126K 
46: R31         Business Acquisitions (Tables)                      HTML     75K 
47: R32         Leases (Tables)                                     HTML     63K 
48: R33         Fair Value Information (Tables)                     HTML     48K 
49: R34         Debt (Tables)                                       HTML     50K 
50: R35         Income Taxes (Tables)                               HTML    108K 
51: R36         Accumulated Other Comprehensive Income (Tables)     HTML     59K 
52: R37         Stock-Based Compensation (Tables)                   HTML     88K 
53: R38         Earnings Per Share ("Eps") (Tables)                 HTML     59K 
54: R39         Business and Products Information (Tables)          HTML     81K 
55: R40         Share Repurchase Program (Tables)                   HTML     41K 
56: R41         Accounting Policies - Property, Plant and           HTML     41K 
                Equipment and Depreciation (Details)                             
57: R42         Accounting Policies - Goodwill and Other            HTML     44K 
                Intangible Assets (Details)                                      
58: R43         Accounting Policies - Revenue Recognition and       HTML     60K 
                Accounts Receivable (Details)                                    
59: R44         Accounting Policies - Income Taxes (Details)        HTML     32K 
60: R45         Discontinued Operations - Narratives (Details)      HTML     59K 
61: R46         Discontinued Operations - Summary of Income         HTML     61K 
                (Details)                                                        
62: R47         Discontinued Operations - Summary of Balance Sheet  HTML     65K 
                (Details)                                                        
63: R48         Discontinued Operations- Summary of Cashflow        HTML     41K 
                (Details)                                                        
64: R49         Restructuring - Restructuring Expense (Details)     HTML     41K 
65: R50         Restructuring - Narrative (Details)                 HTML     61K 
66: R51         Restructuring - Accrual and Payment Activity        HTML     39K 
                (Details)                                                        
67: R52         Goodwill - Narrative (Details)                      HTML     32K 
68: R53         Goodwill - Summary of Goodwill (Details)            HTML     47K 
69: R54         Supplemental Balance Sheet Information - Accounts   HTML     49K 
                receivable (Details)                                             
70: R55         Supplemental Balance Sheet Information -            HTML     40K 
                Inventories (Details)                                            
71: R56         Supplemental Balance Sheet Information - Narrative  HTML     39K 
                (Details)                                                        
72: R57         Supplemental Balance Sheet Information - Property,  HTML     57K 
                Plant and Equipment (Details)                                    
73: R58         Supplemental Balance Sheet Information -            HTML     46K 
                Intangible Assets (Details)                                      
74: R59         Supplemental Balance Sheet Information - Estimated  HTML     46K 
                Amortization Expense (Details)                                   
75: R60         Supplemental Balance Sheet Information - Accrued    HTML     40K 
                Expenses (Details)                                               
76: R61         Supplemental Balance Sheet Information - Other      HTML     36K 
                Long-Term Liabilities (Details)                                  
77: R62         Business Acquisitions - Narrative (Details)         HTML     57K 
78: R63         Business Acquisitions - Purchase Price Allocation   HTML     71K 
                (Details)                                                        
79: R64         Business Acquisitions - Finite-Lived Intangible     HTML     50K 
                Assets (Details)                                                 
80: R65         Business Acquisitions - Pro-Forma Information       HTML     55K 
                (Details)                                                        
81: R66         Leases - ROU Assets and Lease Liabilities           HTML     42K 
                (Details)                                                        
82: R67         Leases - Cost and Cash Flows From Lease Agreements  HTML     43K 
                (Details)                                                        
83: R68         Leases - Future Minimum Obligations Under           HTML     46K 
                Operating Leases (Details)                                       
84: R69         Fair Value Information (Details)                    HTML     52K 
85: R70         Debt - Debt Balances (Details)                      HTML     55K 
86: R71         Debt - Narratives (Details)                         HTML    103K 
87: R72         Debt - Maturities of Long-Term Debt (Details)       HTML     44K 
88: R73         Income Taxes - Provision for Income Taxes           HTML     70K 
                (Details)                                                        
89: R74         Income Taxes - Narrative (Details)                  HTML     51K 
90: R75         Income Taxes - Reconciliation of Federal Statutory  HTML     61K 
                Rate and Effective Rate (Details)                                
91: R76         Income Taxes - Components of Deferred Tax Assets    HTML     72K 
                and Liabilities (Details)                                        
92: R77         Employee Benefit Plans - Defined Contribution       HTML     32K 
                Plans (Details)                                                  
93: R78         Employee Benefit Plans - Defined Benefit Plans      HTML     39K 
                (Details)                                                        
94: R79         Accumulated Other Comprehensive Income - Changes    HTML     49K 
                in Components of Accumulated Other Comprehensive                 
                Income, net of tax (Details)                                     
95: R80         Accumulated Other Comprehensive Income - Net        HTML     45K 
                Changes in Components of AOCI, Including Tax                     
                Effect (Details)                                                 
96: R81         Stock-Based Compensation - Narrative (Details)      HTML     84K 
97: R82         Stock-Based Compensation - Stock-Based              HTML     49K 
                Compensation Expense (Details)                                   
98: R83         Stock-Based Compensation - Stock Option Activity    HTML     64K 
                (Details)                                                        
99: R84         Stock-Based Compensation - Options Outstanding, by  HTML     56K 
                Exercise Price Range (Details)                                   
100: R85         Stock-Based Compensation - Restricted Stock Units   HTML     54K  
                Activity (Details)                                               
101: R86         Stock-Based Compensation - Performance Shares       HTML     49K  
                Activity (Details)                                               
102: R87         Commitments and Contingencies - Narrative           HTML     36K  
                (Details)                                                        
103: R88         Earnings Per Share ("Eps") (Details)                HTML    100K  
104: R89         Business and Products Information - Narrative       HTML     42K  
                (Details)                                                        
105: R90         Business and Products Information - Net Sales by    HTML     46K  
                Product Category (Details)                                       
106: R91         Business and Products Information - Accrued         HTML     38K  
                Liabilities (Details)                                            
107: R92         Business and Products Information - Property,       HTML     37K  
                plant and equipment (Details)                                    
108: R93         Share Repurchase Program - Narrative (Details)      HTML     37K  
109: R94         Share Repurchase Program - Purchase Activity        HTML     41K  
                (Details)                                                        
111: XML         IDEA XML File -- Filing Summary                      XML    200K  
114: XML         XBRL Instance -- avns-20231231_htm                   XML   2.09M  
110: EXCEL       IDEA Workbook of Financial Report Info              XLSX    192K  
12: EX-101.CAL  XBRL Calculations -- avns-20231231_cal               XML    326K 
13: EX-101.DEF  XBRL Definitions -- avns-20231231_def                XML    755K 
14: EX-101.LAB  XBRL Labels -- avns-20231231_lab                     XML   2.06M 
15: EX-101.PRE  XBRL Presentations -- avns-20231231_pre              XML   1.31M 
11: EX-101.SCH  XBRL Schema -- avns-20231231                         XSD    205K 
112: JSON        XBRL Instance as JSON Data -- MetaLinks              586±   884K  
113: ZIP         XBRL Zipped Folder -- 0001606498-24-000018-xbrl      Zip    641K  


‘EX-97.1’   —   Incentive Compensation Clawback Policy


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
Exhibit 97.1
Avanos Medical, Inc.
Incentive Compensation Clawback Policy
1.0General.
1.1    Avanos Medical, Inc. (the “Company”) has adopted this Policy in accordance with the applicable listing standards of the New York Stock Exchange (“NYSE”) and Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which require listed companies to adopt and comply with a compensation recovery policy.
1.2    The effective date of this Policy is October 2, 2023.
1.3    This Policy supersedes any and all prior Company policies, practices, representations or statements regarding the recovery of incentive compensation.
2.0Definitions. The following words and phrases shall have the following meanings for purposes of this Policy:
1.1Accounting Restatement. An “Accounting Restatement” means any accounting restatement that is required to be prepared due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
1.2Board. The “Board” means the Board of Directors of the Company.
1.3Compensation Committee. The “Compensation Committee” means the Compensation Committee of the Board.
1.4Erroneously Awarded Compensation. “Erroneously Awarded Compensation” is the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or TSR, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount shall be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive-Based Compensation was Received and (ii) the Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the NYSE.
1.5Executive Officer. The term “Executive Officer” means the Company’s principal executive officer, president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of any parent or subsidiary of the Company are deemed “Executive Officers” if they perform such policy-making functions for the Company. Executive Officers include, but are not limited to, the officers identified as executive officers by the Company in the Company’s filings with the SEC pursuant to Item 401(b) of Regulation S-K and the officers required to file reports under Section 16 of the Exchange Act.
1.6Financial Reporting Measure. A “Financial Reporting Measure” is any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measure. Stock price and TSR are also Financial Reporting Measures. A Financial Reporting



Measure need not be presented within the Company’s financial statements or included in a filing with the SEC.
1.7Incentive-Based Compensation. The term “Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Please refer to Appendix A to this Policy for a list of examples of Incentive-Based Compensation.
1.8Policy. “Policy” means this Incentive Compensation Clawback Policy.
1.9Received. Incentive-Based Compensation is deemed “Received” in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.
1.10SEC. “SEC” means the United States Securities and Exchange Commission.
1.11TSR. “TSR” means total stockholder return.
3.0Statement of Policy.
3.1    In the event that, while the Company has a class of securities listed with the NYSE, the Company is required to prepare an Accounting Restatement, the Company will recover reasonably promptly the amount of all Erroneously Awarded Compensation Received by any person who served as an Executive Officer at any time during the performance period for that Incentive-Based Compensation. The recovery will apply to all Erroneously Award Compensation Received by such person during the three completed fiscal years immediately preceding the date that the Company is required to prepare the Accounting Restatement and any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years. For purposes of this Policy, a transition period between the last day of the Company’s previous fiscal year and the first day of its new fiscal year that comprises a period of nine to twelve months would be deemed a completed fiscal year. Notwithstanding the foregoing, the recovery does not apply to Erroneously Awarded Compensation Received: (i) prior to the Effective Date of this Policy or (ii) prior to a person’s beginning service as an Executive Officer.
1.1The Company’s obligation to recover Erroneously Awarded Compensation pursuant to this Policy is not dependent on when the restated financial statements are filed.
1.2For purposes of determining the relevant recovery period under this Policy, the date that the Company is required to prepare an Accounting Restatement is the earliest to occur of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.
1.3The Company must recover Erroneously Awarded Compensation in compliance with this Policy except to the extent that the conditions of paragraphs (i), (ii) or (iii) in this Section 3.4 are met, and the Compensation Committee, or in the absence of such a committee, a majority of the independent directors serving on the Board, has determined that recovery would be impracticable.
i.The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall make a reasonable attempt
2


to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the NYSE.
ii.Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before concluding that it would be impractical to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company shall obtain an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such a violation, and provide such opinion to the NYSE.
iii.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.
1.4The Company shall not indemnify any Executive Officer or former Executive Officer against the loss of Erroneously Awarded Compensation pursuant to this Policy.
1.5The Compensation Committee shall determine, in its sole discretion, the appropriate means to seek recovery of any Erroneously Awarded Compensation.
1.6To the extent an Executive Officer, former Executive Officer or Other Covered Person refuses to pay to the Company any Erroneously Awarded Compensation, the Company shall have the right to sue for repayment or, to the extent legally permitted, to enforce such person’s obligation to make payment by withholding unpaid or future compensation.
1.7The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the U.S. Federal securities laws, including the disclosure required by applicable SEC filings.
4.0Application to Additional Persons.
1.1In addition to the Executive Officers and former Executive Officers, this Policy shall apply to any other employee of the Company or its subsidiaries designated by the Compensation Committee as a person covered by this Policy by notice to the employee (each, an “Other Covered Person”).
1.2Unless otherwise determined by the Compensation Committee or the Board, this Policy shall apply to an Other Covered Person as if such individual was an Executive Officer during the relevant periods described in Section 3.0.
1.3The Compensation Committee or the Board may, in its discretion, limit recovery of Erroneously Awarded Compensation from an Other Covered Person to situations in which an Accounting Restatement was caused or contributed to by the Other Covered Person’s fraud, willful misconduct or gross negligence.
1.4In addition, the Compensation Committee or the Board shall have discretion as to: (i) whether to seek to recover Erroneously Awarded Compensation from an Other Covered Person; (ii) the amount of the Erroneously Awarded Compensation to be recovered from an Other Covered Person; and (iii) the method of recovering any such Erroneously Awarded Compensation from an Other Covered Person. In exercising such discretion, the Compensation Committee or the Board may take into account such considerations as it deems appropriate, including whether the assertion of a claim may violate applicable law or prejudice the interests of the Company in any related proceeding or investigation.
3


5.0Interpretation; Enforcement.
1.1The Compensation Committee shall have full authority to interpret and enforce the Policy to the fullest extent permitted by law.
1.2Any determination by the Compensation Committee with respect to this Policy shall be final, conclusive, and binding on all interested parties.
6.0Non-Exclusivity.
1.1Nothing in this Policy shall be viewed as limiting the right of the Company or the Compensation Committee to pursue recoupment under or as provided by the Company’s plans, awards or employment agreements or the applicable provisions of any law, rule or regulation (including, without limitation, Section 304 of the Sarbanes-Oxley Act of 2002).
7.0Policy Controls.
1.1In the event of any actual or alleged conflict between the provisions of the Policy and the provisions of a similar clause or provision in any agreement between an Executive Officer or former Executive Officer, this Policy shall be controlling and determinative.
8.0Amendment.
1.1The Compensation Committee may amend this Policy, provided that any such amendment does not cause the Policy to violate applicable listing standards of the NYSE or Rule 10D-1 under the Exchange Act.


4


APPENDIX A
Examples of Incentive-Based Compensation
Examples of compensation that constitutes Incentive-Based Compensation for purposes of the Policy include, but are not limited to, the following:
Non-equity incentive plan awards earned based wholly or in part on satisfying a Financial Reporting Measure performance goal;

Bonuses paid from a “bonus pool,” the size of which is determined based wholly or in part on satisfying a Financial Reporting Measure performance goal;

Other cash awards based wholly or in part on satisfying a Financial Reporting Measure performance goal;

Restricted stock, restricted stock units, performance share units, stock options, and stock appreciation rights that are granted or become vested based wholly or in part on satisfying a Financial Reporting Measure performance goal; and

Proceeds received upon the sale of shares acquired through an incentive plan that were granted or vested based wholly or in part on satisfying a Financial Reporting Measure performance goal.
Examples of compensation that does not constitute Incentive-Based Compensation for purposes of the Policy include the following:
Salaries;

Bonuses paid solely at the discretion of the Compensation Committee or Board that are not paid from a bonus pool whose size is determined based wholly or in part on satisfying a Financial Reporting Measure performance goal;

Bonuses paid solely upon satisfying one or more subjective standards (e.g., demonstrated leadership) and/or completion of a specified employment period;

Non-equity incentive plan awards earned solely upon satisfying one or more strategic measures (e.g., consummating a merger or divestiture) or operational measures (e.g., opening a specified number of stores, completion of a project, or increase in market share); and

Equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure performance goal and vesting is contingent solely upon completion of a specified employment period and/or attaining one or more non-Financial Reporting Measures.
5

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed as of:2/21/24
Filed on:2/20/248-K
For Period end:12/31/23
10/2/238-K
11/28/22
 List all Filings 


18 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/02/23  Avanos Medical, Inc.              8-K:2,9    10/02/23   11:244K
 8/09/23  Avanos Medical, Inc.              10-Q        6/30/23   77:7.1M
 7/13/23  Avanos Medical, Inc.              S-8         7/13/23    6:270K
 5/03/23  Avanos Medical, Inc.              10-Q        3/31/23   70:5.3M
 2/21/23  Avanos Medical, Inc.              10-K       12/31/22  116:11M
 8/09/22  Avanos Medical, Inc.              10-Q        6/30/22   73:9.6M
 1/21/22  Avanos Medical, Inc.              8-K:2,9     1/20/22   13:3.6M
 8/03/21  Avanos Medical, Inc.              10-Q        6/30/21   65:5.6M
 7/09/21  Avanos Medical, Inc.              8-K:1,9     7/06/21   11:483K
 2/19/21  Avanos Medical, Inc.              10-K       12/31/20  109:11M
11/03/20  Avanos Medical, Inc.              10-Q        9/30/20   69:5.5M
 5/06/20  Avanos Medical, Inc.              8-K:2,5,9   4/30/20   15:920K
12/30/19  Avanos Medical, Inc.              8-K:5,9    12/30/19   14:277K
 8/07/19  Avanos Medical, Inc.              S-8         8/07/19    5:231K
 5/02/18  Avanos Medical, Inc.              10-Q        3/31/18   72:8.3M
10/31/17  Avanos Medical, Inc.              8-K:5,9    10/31/17    3:356K
 6/23/17  Avanos Medical, Inc.              8-K:5,7,9   6/23/17    3:72K
11/04/14  Avanos Medical, Inc.              8-K:1,2,5,810/31/14   19:5.1M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001606498-24-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 3, 8:03:14.2am ET